SAN DIEGO (AP) — SAN DIEGO (AP) — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter.

On a per-share basis, the San Diego-based company said it had a loss of $3.11.

The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $3.09 per share.

The biopharmaceutical company posted revenue of $297,000 in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $170,000.

For the year, the company reported a loss of $39.5 million, or $13.43 per share. Revenue was reported as $785,000.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ONCT at https://www.zacks.com/ap/ONCT

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News